Current therapeutic approach of osteoarthritis;Enfoque terapéutico actual de la osteoartritis

Reumatologia Clinica

Volumn 1, Issue SUPPL. 2, 2005, Pages

  Espinoza Morales, R ^a   Perez Bastidas M E ^a  

^a Departamento de Reumatología Centro Nacional de Rehabilitación México DF   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77951638238     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/S1699-258X(05)72768-6     Document Type: Article

References (106)

1. Moskowitz R. Osteoarthritis. Diagnosis and medical/surgical management. 3re ed. (2001), Sunders, Philadelphia
2. Loeser R., and Shakoor N. Aging or osteoarthritis: which is the problem?. Rheum Dis Clin N Am 29 (2003) 653-673
3. Mannoni A., Briganti M.P., Di Bari M., Ferrucci L., and Costanzo S. Epidemiological profile of symptomatic osteoarthritis in older adults: a population based study in Dicomano, Italy. Ann Rheum Dis 62 (2003) 576-578
4. Zhang Y., Niu J., Kelly-Hayes M., Chaisson C.E., Aliabadi P., and Felson D.T. Prevalence of symptomatic hand osteoarthritis and its impact on functional status among the elderly: The Framingham Study. Am J Epidemiol 156 (2002) 1021-1027
5. Nevitt M.C., Xu L., Zhang Y., Lui L.Y., Yu W., Lane N.E., et al. Very low prevalence of hip osteoarthritis among Chinese elderly in Beijing, China, compared with whites in the United States: the Beijing osteoarthritis study. Arthritis Rheum 46 (2002) 1773-1779
6. Felson D.T., Nevitt M.C., Zhang Y., Aliabadi P., Baumer B., Gale D., et al. High prevalence of lateral knee osteoarthritis in Beijing Chinese compared with Framingham Caucasian subjects. Arthritis Rheum 46 (2002) 1217-1222
7. Espinosa R., Hernández L., and Arroyo C. Prevalencia de manifestaciones musculoesqueléticas en México. Rev Mex Reumatol 20 (2005) 5
8. Cardiel M.H., and Rojas-Serrano J. Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 20 (2002) 617-624
9. Altman R., Alarcón G., Appelrouth D., Bloch D., Boreinstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 33 (1990) 601-610
10. Altman R., Alarcón G., Appelrouth D., Bloch D., Boreinstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 34 (1991) 505-514
11. Altman R., Asch E., Bloch D., Bole G., Boreinstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum 29 (1986) 1039-1049
12. Woo J., Lau E., Sing C.H., Lee P., Zhang J., Kwok T., et al. Socioeconomic impact of osteoarthritis in Hong Kong: utilization of health and social services, and direct and indirect costs. Arthritis Care Res 49 (2003) 526-534
13. Carmona L., Ballina J., Gabriel R., Laffon A., and EPISER Study Group. The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60 (2001) 1040-1045
14. Espinosa R., Hernández L., and Arroyo C. Patrón de utilización de servicios de salud en México en pacientes con artritis. Rev Mex Reumatol 20 (2005) 20-21
15. Bollen S. Epidemiology of knee injuries: diagnosis and triage. Br J Sports Med 34 (2000) 227-228
16. Manson J.E., and Bassuk S.S. Obesity in the United States: a fresh look at its high toll. JAMA 289 (2003) 229-230
17. Hill C.L., Suk S.G., Gale D., Totterman S., Gale M.E., and Felson D.T. Cruciate ligament integrity in osteoarthritis of the knee. Arthritis Rheum 52 (2005) 794-799
18. Reijman M., Hazes J.M.W., Pols H.A.P., Koes B.W., and Bierma-Zeinstra S.M.A. Acetabular dysplasia predicts incident osteoarthritis of the hip: the Rotterdam study. Arthritis Rheum 52 (2005) 787-793
19. Felson D.T. Risk factors for osteoarthritis: understanding joint vulnerability. Clin Orthop Relat Res 427 Suppl (2004) 16-21
20. Felson D.T. Preventing knee and hip osteoarthritis. Bull Rheum Dis 47 (1998) 1-4
21. Slemenda C., Brandt K.D., Heilman D.K., Mazzuca S., Braunstein E.M., Katz B.P., et al. Quadriceps weakness and osteoarthritis of the knee. Ann Intern Med 127 (1997) 97-104
22. Superio-Cabuslay E., Ward M.M., and Loring K.R. Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with nonsteroidal antiinflammatory dug treatment. Arthritis Care Res 9 (1996) 292-301
23. Mazzuca S.A., Brandt K.D., Katz B.P., Hanna M.P., and Mefi C.A. Reduced utilization and cost of primary care clinic visits resulting from self-care education for patients with osteoarthritis of the knee. Arthritis Rheum 42 (1999) 1267-1273
24. Mazzuca S.A., Brandt K.D., Katz B.P., Chambers M., Byrd D., and Hanna M. Effects of self-care education on the health status of inner-city patients with osteoarthritis of the knee. Arthritis Rheum 40 (1997) 1466-1474
25. Weinberger M., Tierney V.W., Booher P., and Katz B.P. Can the provision of information to patients with osteoarthritis improve functional status? A randomized, controlled trial. Arthritis Rheum 32 (1989) 1577-1583
26. Felson D.T., Anderson J.J., Naimark A., Walker A.M., and Melnan R.F. Obesity and knee osteoarthritis. Ann Intern Med 109 (1988) 18-24
27. Felson D.T., Zhang Y., Hannan M.T., and Anderson J.J. Risk factors for incident radiographic knee osteoarthritis in the elderly. Arthritis Rheum 40 (1997) 728-733
28. Tepper S., and Hochberg M.C. Factors associated with hip osteoarthritis: data from the First National Health and Nutrition Examination Survey (NHANES I). Am J Epidemiol 137 (1993) 1081-1088
29. Carman W.J., Sowers M., Hawthorne V.M., and Weissfeld L.A. Obesity as a risk factor for osteoarthritis of the hand and wrist: a prospective study. Am Med J Epidemiol 139 (1994) 119-129
30. Felson D.T., Zhang Y., Anthony J.M., Naimark A., and Anderson J.J. Weigth loss reduces the risk of symptomatic knee osteoarthritis in women. Ann Intern Med 116 (1992) 535-539
31. Roddy E., Zhang W., and Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis 64 (2005) 544-548
32. Brand S.A., and Crowninshield R.D. The effect of cane use on hip contact force. Clin Orthop 147 (1980) 181-184
33. Keating E.M., Faris P.M., Ritter M.A., and Kane J. Use of lateral heel and sole wedges in the treatment of medial osteoarthritis of the knee. Orthop Rev 22 (1993) 921-924
34. Marks R., Quinney A.H., and Wessel J. Reliability and validity of measurement of position sense in women with osteoarthritis of the knee. J Rheumatol 20 (1993) 1919-1924
35. Cushnagan J., MacCarthry C., and Dieppe P.A. Taping the patella medially: a new treatment for osteoarthritis of the knee joint?. Br Med J 308 (1988) 753-755
36. Zhang W.Y., and Li-Wan-Po A. The effectiveness of topically applied capsaicin. A meta-analysis. Eur J Clin Pharmacol 46 (1994) 517-522
37. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomized controlled trials. BMJ.
38. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 62 (2003) 1145-1155
39. American College of Rheumatology. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 43 (2000) 1905-1915
40. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduces the pain of osteoarthritis? A meta-analysis of randomized placebo controlled trials. Ann Rheum Dis 63 (2004) 901-907
41. Amadio P., and Cummings D.M. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res 34 (1983) 59-66
42. Zoppi M., Peretti G., and Boccard E. Placebo-controlled study of the analgesic efficacy of an effervescent formulation of 500 mg paracetamol in arthritis of the knee or hip. Eur J Pain 16 (1995) 42-48
43. Miceli-Richard C., Le Bars M., Schmidely N., and Dougados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 63 (2004) 923-930
44. Pincus T., Koch G., Lei H., Mangal B., Sokka T., Moskowitz R., et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomized, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63 (2004) 931-939
45. Neame R., Zhang W., and Doherty M. Historic issue of the annals: three papers examines paracetamol in osteoarthritis. Ann Rheum Dis 63 (2004) 897-900
46. Pincus T., Fort J.F., Mangal B., Koch G., Wolfe F., Moskowitz R., et al. Patient Preference for Placebo, Acetaminophen (paracetamol), or Celebrex Effectiveness Study (PACES-1): a double-blinded, randomized, crossover clinical trial in patients with osteoarthritis of the hip or knee [resumen]. Ann Rheum Dis 62 Suppl I (2003) 73
47. Williams H.J., Ward J.R., Egger M.J., Neuner R., Brooks R.H., Clegg D.O., et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 36 (1993) 1196-1206
48. Bradley J.D., Brandt K.D., Katz B.P., Kalasinski L.A., and Ryan S.I. Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. J Rheumatol 19 (1992) 1950-1954
49. Pincus T., Koch G.G., and Sokka T. A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 44 (2001) 1587-1598
50. Geba G.P., Weaver A.L., Polis A.B., Dixon M.E., Scnitzer T.J., and Vioxx ACT (VACT) Group. Vioxx ACT (VACT) Group. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287 (2002) 64-71
51. Schnitzer T.J., Kamin M., and Olson W.H. Tramadol allows reduction of naproxen dose among patientes with naproxen-responsive osteoarthritis pain. Arthritis Rheum 42 (1999) 1370-1377
52. Mullican W.S., and Lacy J.R. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the managament of chronic pain: a comparative trail. Clin Ther 23 (2001) 1429-1445
53. Case J.P., Baliunas A.J., and Block J.A. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 163 (2003) 169-178
54. Chard J.A., Tallon D.J., and Dieppe P.A. Epidemiology of research into interventions for the treatment of osteoarthritis of the knee joint. Ann Rheum Dis 59 (2000) 414-418
55. Tramer M.r., Moore R.A., Reyanolds D.J., and McQuay H.J. Quantitative estimation of rare adverse events which follow biological progression: a new model applied to chronic NSAID use. Pain 85 (2000) 169-182
56. Johnson A.G., and NSDAIDs and increased blood pressure. What is the clinical significance?. Drug Saf 17 (1997) 277-289
57. Bleumink G.S., Feenstra J., Sturkenboom M.C., and Stricker B.H. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 63 (2003) 525-534
58. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 106 Suppl 5B (1999) 13-24
59. Courtney P., and Doherty M. Key questions concerning paracetamol and NSAIDs for osteoarthritis. Ann Rheum Dis 61 (2002) 767-773
60. Brandt K.D. Non-surgical treatment of osteoarthritis: a half century of "advances". Ann Rheum Dis 63 (2004) 117-122
61. Bjordal J.M., Ljunggren A.E., Klovning A., and Slørdal L. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomized placebo controlled trials. BMJ 329 (2004)
62. Silverstein F.E., Graham D.Y., Senior J.R., Davies H.W., Struthers B.J., Bittman R.M., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non steroidal antiinflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
63. Yeomans N.D., Tulassay Z., Juhasz L., Racz I., Howard J.M., Van Rensburg C.J., et al. A comparison of omeprazole with ranitidine for ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med 338 (1998) 719-726
64. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., and Pincus T. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
65. Bombardier C., Laine L., Reicin A., Shapiro D., and Burgos-Vargas R. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2000) 1520-1528
66. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 96 (1999) 7563-7568
67. Fenton C., Keating G.M., and Wagstaff A.J. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain. Drugs 64 (2004) 1231-1261
68. Edwards J.E., McQuay H.J., and Moore R.A. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain 111 (2004) 286-296
69. Lyseng-Williamson K.A., and Curran M.P. Lumiracoxib. Drugs 64 (2004) 2237-2246
70. Hawkey C.C., Svoboda P., Fiedorowicz-Fabrycy I.F., Nasonov E.L., Pikhlak E.G., Cousin M., et al. Gastroduodenal safety and tolerability of lumiracoxib compared with ibuprofen and celecoxib in patients with osteoarthritis. J Rheumatol 31 (2004) 1804-1810
71. Food and Drugs Administration. Disponible en: http://www.fda.gov/cder/drug/infopage/COX2/default.htms
72. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., et al., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
73. Graham D.J., Campen D., Hui R., Spence M., Cheetham C., Levy G., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
74. Nussmeier N.A., Whelton A.A., Brown M.T., Langford R.M., Hoeft A., Parlow J.L., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352 (2005) 1081-1091
75. Knowles S.R., Phillips E.J., Wong G., and Shear N.H. Serious dermatologic reaction associated with valdecoxib: report of two cases. J Am Acad Dermatol 51 (2004) 1028-1029
76. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 63 (2004) 11-14
77. Reginster J.Y., Leroisy R., and Rovati L.C. Long-term effects of glucosamine sulfate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
78. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., and Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162 (2002) 2113-2123
79. Richy F., Bruyere O., Ethgen O., Cucherat M., Henrotin Y., and Reginster J.Y. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 163 (2003) 1514-1522
80. McAlindon T.E., LaValley M.P., Gulin J.P., and Felson D.T. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 283 (2000) 1469-1475
81. Michel B.A., Stucki G., Frey D., De Vathaire F., Vignon E., Bruehlmann P., et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 52 (2005) 779-786
82. Yaron M., Shirazi I., and Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthritis Cartilage 7 (1999) 272-280
83. Felisaz N., Boumediene K., Ghayor C., Herrouin J.F., Bogdanowicz P., et al. Stimulating effect of diacerein on TGF-beta1 and beta2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthritis Cartilage 7 (1999) 255-264
84. Pelletier J.P., Yaron M., Haraoui B., Cohen P., Nahir M.A., Choquette D., et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum 43 (2000) 2339-2348
85. Dougados M., Nguyen M., Berdah L., Mazieres B., Vignon E., and Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum 44 (2001) 2539-2547
86. Appelboom T., Schuermans J., Verbruggen G., Henrotin Y., and Reginster J.Y. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 30 (2001) 242-247
87. Lequesne M., Maheu E., Cadet C., and Dreiser R.L. Structural effect of avocado/ soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Rheum 47 (2002) 50-58
88. Henrotin Y.E., Sánchez C., Deberg M.A., Piccardi N., Guillou G.B., Msika P., et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and pro-inflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 30 (2003) 1825-1834
89. Kut-Lasserre C., Miller C.C., Ejeil A.L., Gogly B., Dridi M., Piccardi N., et al. Effect of avocado and soybean unsaponifiables on gelatinase A (MMP-2), stromelysin 1 (MMP-3), and tissue inhibitors of matrix metalloproteinase (TIMP-1 and TIMP-2) secretion by human fibroblasts in culture. J Periodontol 72 (2001) 1685-1694
90. Ernst E. Avocado-soybean unsaponifiables (ASU) for osteoarthritis- a systematic review. Clin Rheumatol 22 (2003) 285-288
91. Little C.V., and Parsons T. Herbal therapy for treating osteoarthritis. Cochrane Database Syst Rev 1 (2001) CD002947
92. Walker-Bone K. "Natural remedies" in the treatment of osteoarthritis. Drugs Aging 20 (2003) 517-526
93. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 38 (1995) 1541-1546
94. Papachristou G., Anagnostou S., and Katsorhis T. The effect of intra-articular hydrocortisone injection on the articular cartilage of rabbits. Acta Orthop Scand (1997) 132-134
95. Creamer P. Intra-articular corticosteroid treatment in osteoarthritis. Curr Opin Rheumatol 11 (1999) 417-421
96. Raynauld J.P., Buckland-Wright C.H., Ward R., Choquette D., Haraoui B., Martel-Pelltier J., et al. Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee. A randomized, double-blind, placebo-controlled trial. Arthritis Rheum 48 (2003) 370-377
97. Peyron J.G. Intraarticular hyaluronan injections in the tratment of osteoarthritis: state-of-the art review. J Rheumatol 20 Suppl 39 (1993) 10-15
98. Gossec D.M. Intra-articular treatments in osteoarthritis: from the symptomatic to the structure modifying. Ann Rheum Dis 63 (2004) 478-482
99. Pasquali-Ronchetti I., Guerra D., Taparelli F., Boraldi F., Bergamini G., Mori G., et al. Morphological analysis of knee synovial membrane biopsies from a randomized controlled clinical study comparing the effects of sodium hyaluronate (Hyalgan) and methylprednisolone acetate (Depomedrol) in osteoarthritis. Rheumatology Oxford 40 (2001) 158-169
100. Lo G.H., Lavalley M., MacAlidon T., and Felson D.T. Intraarticular hyaluronic acid in treatment of knee osteoarthritis. A meta-analysis. JAMA 290 (2003) 3115-3121
101. Whang C.T., Lin J., Cang C.J., Lin Y.T., and Hou S.M. Therapeutics effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg 84 (2004) 538-545
102. Wobig M., Bach G., Beks P., Dickut A., Runzheimer J., Schwieger G., et al. The role of elastoviscocity in the efficacy of viscosupplemetation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower molecular weight hyaluronan. Clin Ther 21 (1999) 1549-1562
103. Listrat V., Ayral X., Paternella F., Bonvarlet J.P., Simonnet J., Amor B., et al. Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage 5 (1997) 153-160
104. Jubb R.W., Piva S., Beinat L., Dacre J., Gishen P., and on behalf of the UK Hyalgan Study Group. Structure modification in osteoarthritis with intra- articular sodium Hyaluronate of man. 500-730 KDa. Ann Rheum Dis 60 Suppl 1 (2001) 46.
105. Arrich J., Piribauer F., Mad P., Schmid D., Klaushofer K., and Mullner M. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 172 (2005) 1039-1043
106. a ed. (2002), IM&C, Madrid